LifeTech Capital Comments on Neoprobe, Maintains Strong Speculative Buy

LifeTech Capital provided color on Neoprobe

in a research report published today. LifeTech Capital maintains its Neoprobe Strong Speculative Buy rating and $5.75 price target. In the report, LifeTech Capital states, "We believe the weakness in Neoprobe shares is the result of significant confusion between Neoprobe's LymphoSeek® FDA-approval strategy, the FDA approval guidelines and physician adoption. We also note that RIGScan®, which we expect to be significantly larger to Neoprobe's longterm financial success, is being wrongfully ignored in valuation calculations." Shares of Neoprobe were trading at $3.83 at the time of posting, down 1.29% from Tuesday's market close.